Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky, USA.
Nanomedicine. 2013 Apr;9(3):398-407. doi: 10.1016/j.nano.2012.08.002. Epub 2012 Sep 5.
The aims were to determine the biodistribution, translocation, and persistence of nanoceria in the brain and selected peripheral organs. Nanoceria is being studied as an anti-oxidant therapeutic. Five, 15, 30, or 55 nm ceria was iv infused into rats which were terminated 1, 20, or 720 h later. Cerium was determined in blood, brain, liver, and spleen. Liver and spleen contained a large percentage of the dose, from which there was no significant clearance over 720 h, associated with adverse changes. Very little nanoceria entered brain parenchyma. The results suggest brain delivery of nanoceria will be a challenge.
This team of investigators revealed that nanoceria, which is being studied as an anti-oxidant, has very limited uptake by the brain regardless of the range of sizes studied, suggesting major challenges in the application of this novel approach in the central nervous system.
目的是确定纳米氧化铈在大脑和选定的外周器官中的分布、转移和持久性。纳米氧化铈作为一种抗氧化治疗剂正在研究中。将 5、15、30 或 55nm 的氧化铈 通过静脉注射到大鼠体内，然后在 1、20 或 720 小时后处死。铈在血液、大脑、肝脏和脾脏中进行了测定。肝脏和脾脏中含有很大比例的剂量，在 720 小时内没有明显的清除，伴随着不良反应的发生。很少有纳米氧化铈进入脑组织。结果表明，向大脑输送纳米氧化铈将是一个挑战。
该研究小组的研究人员揭示，纳米氧化铈作为一种抗氧化剂，其被大脑摄取的量非常有限，无论研究的粒径范围如何，这表明在中枢神经系统中应用这种新方法存在重大挑战。
